DDInter948 DDInter1702
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Sorafenib {u} (Compound) treats {v} (Disease) liver cancer
Sorafenib {u} (Compound) binds {v} (Gene) BRAF
Sorafenib {u} (Compound) upregulates {v} (Gene) TSC22D3
Sorafenib {u} (Compound) downregulates {v} (Gene) MCM3
Sorafenib {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Sorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tacrine
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Sorafenib (Compound) resembles Vismodegib (Compound)
Sorafenib (Compound) treats liver cancer (Disease)
Sorafenib (Compound) binds BRAF (Gene)
Sorafenib (Compound) upregulates TSC22D3 (Gene)
Sorafenib (Compound) downregulates MCM3 (Gene)
Sorafenib (Compound) causes Hepatobiliary disease (Side Effect)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Sorafenib may lead to a major life threatening interaction when taken with Ibutilide